Peking University People's Hospital: Neoplasm, Residual trials

The registry lists 12 Neoplasm, Residual studies with Peking University People's Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 2Phase 3 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2
• MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCNot yet recruitingNCT07873086Not applicable
• Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AMLRecruitingNCT07500441
• CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTRecruitingNCT07441291Phase 3
• To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)RecruitingNCT07291921
• To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCTRecruitingNCT07280494Phase 1
• Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung CancerRecruitingNCT06930807Not applicable
• Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain ReactionRecruitingNCT06211166
• Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRDRecruitingNCT05408897
• A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid BiopsySuspendedNCT05867901
• Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After AllotransplantStatus unknownNCT03297528Phase 2
• Interferon α for the Therapy of Minimal Residual DiseaseStatus unknownNCT02185261Not applicable